Do analysts rate BNR or CMPX?

Compass Therapeutics has a consensus target price of $11.77, indicating a potential upside of 390.38%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Compass Therapeutics is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Compass Therapeutics 1 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.88

Does the media favor BNR or CMPX?

In the previous week, Burning Rock Biotech and Burning Rock Biotech both had 3 articles in the media. Compass Therapeutics' average media sentiment score of 1.72 beat Burning Rock Biotech's score of 0.63 indicating that Compass Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Burning Rock Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compass Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts recommend PRTC or BNR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, PRTC or BNR?

Burning Rock Biotech has higher revenue and earnings than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health $4.66M 91.01 -$109.74M N/A N/A Burning Rock Biotech $514.43M 0.21 -$7.92M -$0.82 N/A

Do analysts rate LRMR or BNR?

Larimar Therapeutics presently has a consensus target price of $11.67, suggesting a potential upside of 190.94%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Larimar Therapeutics is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Larimar Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 3 Strong Buy rating(s) 3.10 Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to LRMR or BNR?

In the previous week, Burning Rock Biotech had 1 more articles in the media than Larimar Therapeutics. MarketBeat recorded 3 mentions for Burning Rock Biotech and 2 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 1.71 beat Burning Rock Biotech's score of 0.63 indicating that Larimar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Burning Rock Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate BNR or FHTX?

Foghorn Therapeutics has a consensus target price of $11.43, indicating a potential upside of 90.48%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Foghorn Therapeutics is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Foghorn Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88

Do analysts rate ARCT or BNR?

Arcturus Therapeutics presently has a consensus target price of $20.00, suggesting a potential upside of 31.67%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Arcturus Therapeutics is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcturus Therapeutics 1 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.60 Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to ARCT or BNR?

In the previous week, Arcturus Therapeutics and Arcturus Therapeutics both had 3 articles in the media. Arcturus Therapeutics' average media sentiment score of 0.66 beat Burning Rock Biotech's score of 0.63 indicating that Arcturus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Burning Rock Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Burning Rock Biotech (BNR) Competitors

$10.19 +0.19 (+1.90%)

As of 08/28/2026 01:47 PM Eastern

Compare

BNR vs. CMPX, PRTC, LRMR, FHTX, and ARCT

Should you buy Burning Rock Biotech stock or one of its competitors? Burning Rock Biotech's main competitors and comparable companies include Compass Therapeutics (CMPX), PureTech Health (PRTC), Larimar Therapeutics (LRMR), Foghorn Therapeutics (FHTX), and Arcturus Therapeutics (ARCT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Burning Rock Biotech compare to Compass Therapeutics?

Burning Rock Biotech (NASDAQ:BNR) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Compass Therapeutics has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -11.57%. Burning Rock Biotech's return on equity of -10.98% beat Compass Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-11.57%	-10.98%	-7.33%
Compass Therapeutics	N/A	-38.71%	-34.72%

Burning Rock Biotech has a beta of 1.34, indicating that its stock price is 34% more volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market.

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by company insiders. Comparatively, 18.7% of Compass Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Compass Therapeutics has a consensus target price of $11.77, indicating a potential upside of 390.38%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Compass Therapeutics is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Burning Rock Biotech has higher revenue and earnings than Compass Therapeutics. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$514.43M	0.21	-$7.92M	-$0.82	N/A
Compass Therapeutics	$850K	508.49	-$66.49M	-$0.40	N/A

In the previous week, Burning Rock Biotech and Burning Rock Biotech both had 3 articles in the media. Compass Therapeutics' average media sentiment score of 1.72 beat Burning Rock Biotech's score of 0.63 indicating that Compass Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Burning Rock Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compass Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Compass Therapeutics beats Burning Rock Biotech on 10 of the 16 factors compared between the two stocks.

How does Burning Rock Biotech compare to PureTech Health?

PureTech Health (NASDAQ:PRTC) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

In the previous week, Burning Rock Biotech had 3 more articles in the media than PureTech Health. MarketBeat recorded 3 mentions for Burning Rock Biotech and 0 mentions for PureTech Health. Burning Rock Biotech's average media sentiment score of 0.63 beat PureTech Health's score of 0.00 indicating that Burning Rock Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
PureTech Health	Neutral
Burning Rock Biotech	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Burning Rock Biotech has higher revenue and earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A
Burning Rock Biotech	$514.43M	0.21	-$7.92M	-$0.82	N/A

PureTech Health has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -11.57%. PureTech Health's return on equity of 0.00% beat Burning Rock Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	N/A	N/A	N/A
Burning Rock Biotech	-11.57%	-10.98%	-7.33%

PureTech Health has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.34, suggesting that its stock price is 34% more volatile than the broader market.

0.0% of PureTech Health shares are owned by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are owned by institutional investors. 5.3% of PureTech Health shares are owned by company insiders. Comparatively, 30.3% of Burning Rock Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Burning Rock Biotech beats PureTech Health on 7 of the 11 factors compared between the two stocks.

How does Burning Rock Biotech compare to Larimar Therapeutics?

Larimar Therapeutics (NASDAQ:LRMR) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

Burning Rock Biotech has higher revenue and earnings than Larimar Therapeutics. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A
Burning Rock Biotech	$514.43M	0.21	-$7.92M	-$0.82	N/A

Larimar Therapeutics has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.34, suggesting that its stock price is 34% more volatile than the broader market.

Larimar Therapeutics presently has a consensus target price of $11.67, suggesting a potential upside of 190.94%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Larimar Therapeutics is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Burning Rock Biotech had 1 more articles in the media than Larimar Therapeutics. MarketBeat recorded 3 mentions for Burning Rock Biotech and 2 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 1.71 beat Burning Rock Biotech's score of 0.63 indicating that Larimar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Burning Rock Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.9% of Larimar Therapeutics shares are held by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are held by institutional investors. 4.0% of Larimar Therapeutics shares are held by insiders. Comparatively, 30.3% of Burning Rock Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Larimar Therapeutics has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -11.57%. Burning Rock Biotech's return on equity of -10.98% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-137.39%	-97.65%
Burning Rock Biotech	-11.57%	-10.98%	-7.33%

Summary

Larimar Therapeutics and Burning Rock Biotech tied by winning 8 of the 16 factors compared between the two stocks.

How does Burning Rock Biotech compare to Foghorn Therapeutics?

Burning Rock Biotech (NASDAQ:BNR) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

In the previous week, Burning Rock Biotech had 2 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 3 mentions for Burning Rock Biotech and 1 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 1.44 beat Burning Rock Biotech's score of 0.63 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Burning Rock Biotech	Positive
Foghorn Therapeutics	Positive

Burning Rock Biotech has a beta of 1.34, suggesting that its share price is 34% more volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.89, suggesting that its share price is 189% more volatile than the broader market.

Burning Rock Biotech has higher revenue and earnings than Foghorn Therapeutics. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$514.43M	0.21	-$7.92M	-$0.82	N/A
Foghorn Therapeutics	$36.74M	9.70	-$74.28M	-$0.98	N/A

Burning Rock Biotech has a net margin of -11.57% compared to Foghorn Therapeutics' net margin of -175.78%. Foghorn Therapeutics' return on equity of 0.00% beat Burning Rock Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-11.57%	-10.98%	-7.33%
Foghorn Therapeutics	-175.78%	N/A	-31.17%

Foghorn Therapeutics has a consensus target price of $11.43, indicating a potential upside of 90.48%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Foghorn Therapeutics is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 61.5% of Foghorn Therapeutics shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by company insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Foghorn Therapeutics beats Burning Rock Biotech on 10 of the 17 factors compared between the two stocks.

How does Burning Rock Biotech compare to Arcturus Therapeutics?

Arcturus Therapeutics (NASDAQ:ARCT) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

Burning Rock Biotech has higher revenue and earnings than Arcturus Therapeutics. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$82.03M	5.26	-$65.78M	-$3.31	N/A
Burning Rock Biotech	$514.43M	0.21	-$7.92M	-$0.82	N/A

Arcturus Therapeutics has a beta of 2.39, suggesting that its stock price is 139% more volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.34, suggesting that its stock price is 34% more volatile than the broader market.

Arcturus Therapeutics presently has a consensus target price of $20.00, suggesting a potential upside of 31.67%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Arcturus Therapeutics is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Burning Rock Biotech has a net margin of -11.57% compared to Arcturus Therapeutics' net margin of -317.62%. Burning Rock Biotech's return on equity of -10.98% beat Arcturus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-317.62%	-46.54%	-36.46%
Burning Rock Biotech	-11.57%	-10.98%	-7.33%

94.5% of Arcturus Therapeutics shares are held by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are held by institutional investors. 17.8% of Arcturus Therapeutics shares are held by company insiders. Comparatively, 30.3% of Burning Rock Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Arcturus Therapeutics and Arcturus Therapeutics both had 3 articles in the media. Arcturus Therapeutics' average media sentiment score of 0.66 beat Burning Rock Biotech's score of 0.63 indicating that Arcturus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcturus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Burning Rock Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Arcturus Therapeutics beats Burning Rock Biotech on 9 of the 16 factors compared between the two stocks.

Get Burning Rock Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNR vs. The Competition

Export

Metric	Burning Rock Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$107.18M	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-12.43	11.62	273.16	25.45
Price / Sales	0.21	1,295.87	605.06	76.64
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	1.40	16.53	12.98	6.14
Net Income	-$7.92M	-$22.80M	$3.48B	$348.86M
7 Day Performance	4.19%	-0.31%	0.13%	-0.80%
1 Month Performance	15.14%	9.80%	7.08%	4.13%
1 Year Performance	19.13%	55.66%	24.67%	15.17%

Burning Rock Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNR Burning Rock Biotech	0.7697 of 5 stars	$10.19 +1.9%	N/A	+19.1%	$107.18M	$514.43M	N/A	1,390	Upcoming Earnings Analyst Downgrade Gap Down High Trading Volume
CMPX Compass Therapeutics	2.8722 of 5 stars	$2.53 +5.4%	$11.77 +365.2%	-31.2%	$432.21M	$850K	N/A	20	News Coverage
PRTC PureTech Health	0.0131 of 5 stars	$17.42 flat	N/A	N/A	$424.04M	$4.66M	N/A	100
LRMR Larimar Therapeutics	3.709 of 5 stars	$4.16 +2.7%	$11.67 +180.4%	+10.8%	$420.73M	N/A	N/A	30	Positive News
FHTX Foghorn Therapeutics	2.314 of 5 stars	$6.85 -0.3%	$11.43 +66.8%	+18.6%	$407.98M	$30.91M	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNR) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Burning Rock Biotech (BNR) Competitors

BNR vs. CMPX, PRTC, LRMR, FHTX, and ARCT

How does Burning Rock Biotech compare to Compass Therapeutics?

Summary

How does Burning Rock Biotech compare to PureTech Health?

Summary

How does Burning Rock Biotech compare to Larimar Therapeutics?

Summary

How does Burning Rock Biotech compare to Foghorn Therapeutics?

Summary

How does Burning Rock Biotech compare to Arcturus Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR vs. The Competition

Burning Rock Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Burning Rock Biotech (BNR) Competitors

BNR vs. CMPX, PRTC, LRMR, FHTX, and ARCT

How does Burning Rock Biotech compare to Compass Therapeutics?

Is BNR or CMPX more profitable?

Which has more risk and volatility, BNR or CMPX?

Do insiders & institutionals hold more shares of BNR or CMPX?

Do analysts rate BNR or CMPX?

Which has stronger earnings and valuation, BNR or CMPX?

Does the media favor BNR or CMPX?

Summary

How does Burning Rock Biotech compare to PureTech Health?

Does the media prefer PRTC or BNR?

Do analysts recommend PRTC or BNR?

Which has better valuation and earnings, PRTC or BNR?

Is PRTC or BNR more profitable?

Which has more volatility & risk, PRTC or BNR?

Do institutionals and insiders believe in PRTC or BNR?

Summary

How does Burning Rock Biotech compare to Larimar Therapeutics?

Which has stronger earnings and valuation, LRMR or BNR?

Which has more risk and volatility, LRMR or BNR?

Do analysts rate LRMR or BNR?

Does the media refer more to LRMR or BNR?

Do institutionals and insiders hold more shares of LRMR or BNR?

Is LRMR or BNR more profitable?

Summary

How does Burning Rock Biotech compare to Foghorn Therapeutics?

Does the media favor BNR or FHTX?

Which has more risk & volatility, BNR or FHTX?

Which has preferable valuation and earnings, BNR or FHTX?

Is BNR or FHTX more profitable?

Do analysts rate BNR or FHTX?

Do insiders and institutionals believe in BNR or FHTX?

Summary

How does Burning Rock Biotech compare to Arcturus Therapeutics?

Which has better valuation and earnings, ARCT or BNR?

Which has more risk and volatility, ARCT or BNR?

Do analysts rate ARCT or BNR?

Is ARCT or BNR more profitable?

Do institutionals and insiders have more ownership in ARCT or BNR?

Does the media refer more to ARCT or BNR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR vs. The Competition

Burning Rock Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools